MLNT Melinta Therapeutics

Melinta Therapeutics to Present at Upcoming Investor Conferences

Melinta Therapeutics to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and CEO of Melinta, will present at the following upcoming investor conferences:

  • 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Monday Oct. 1 at 8:55 a.m. Eastern Time. A webcast can be accessed from the following URL: .

     
  • Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday Oct. 2 at 10:00 a.m. Eastern Time. A webcast can be accessed from the following URL: .

Live and archived webcasts of the presentations will also be accessible from Melinta’s Investor Relations website at .

About Melinta Therapeutics

Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit for more information.

For More Information:

Media Inquiries:

David Belian

(203) 848-6276

Investor Inquiries:

Lisa DeFrancesco

(908) 617-1358

EN
25/09/2018

Underlying

MLNTMelinta Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Melinta Therapeutics

 PRESS RELEASE
Free
MLNT Melinta Therape...

Melinta Therapeutics Announces Termination of Merger Agreement and Ten...

Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common sto...

June 24, 2020 1 EN
 PRESS RELEASE
Free
MLNT Melinta Therape...

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharm...

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio  MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million ...

June 9, 2020 1 EN
 PRESS RELEASE
Free
MLNT Melinta Therape...

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Compa...

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed today that the Company’s agreement with funds managed by Deerfield Management Company, L.P., the lenders under the Company’s senior cred...

March 4, 2020 1 EN
 PRESS RELEASE
Free
MLNT Melinta Therape...

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Pr...

Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MORRISTOWN, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infe...

February 13, 2020 1 EN
 PRESS RELEASE
Free
MLNT Melinta Therape...

Melinta Therapeutics Announces Restructuring Support Agreement with it...

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into a Restructuring Support Agreement (the “Ag...

December 27, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch